DOCSLIB.ORG

Virbac Product Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Virbac Product Guide VIRBAC PRODUCT GUIDE Shaping the future of animal health TABLE OF CONTENTS WHO IS VIRBAC Complete Product List with Product Numbers ........................... 4-5 Introducing Stelfonta® ........................................................................... 6 Virbac is driven by a passion for enhancing the health of companion animals. Ear Health ................................................................................................. 8 In the U.S., our focus is solely on meeting the unique needs of veterinary Skin Health ............................................................................................... 9 professionals caring for dogs, cats and other companion animals. We Dental Health ......................................................................................... 12 recognize that meeting those needs starts with listening. Heartworm ............................................................................................. 17 Ultimately, the essence of Virbac U.S. is found in our relationships with our Parasiticides ........................................................................................... 19 veterinarians. It is through these relationships that, together, we can find the Supplements .......................................................................................... 22 right answers by first asking the right questions. Antibiotics ............................................................................................. 24 In-Clinic Use ........................................................................................... 25 Product Inserts/Disclosures ......................................................... 27-39 If you have any questions regarding these products, please contact Virbac Veterinary us.virbac.com Technical Product Support at 1.800.338.3659 or your local Virbac Representative. PRODUCT LISTING PRODUCT LISTING Product Description Product No. Size Product Description Product No. Size Product Description Product No. Size Product Description Product No. Size ANTIBIOTICS PAGE 24 DENTAL HEALTH PAGE 12 HEARTWORM PAGE 17 SUPPLEMENTS PAGE 22 BIOMOX® (amoxicillin) Oral Suspension (50 mg/mL) 92515 15 mL C.E.T. AQUADENT® FR3SH® Dental Solution 90508 8.45 fl oz. IVERHART MAX® Chew (ivermectin/pyrantel pamoate/praziquantel) - Display - Toy 50102 10 Boxes of 6 Doses ANXITANE® (L-Theanine) Chewable Tablets - S 50 mg 10432 30 ct. BIOMOX® (amoxicillin) Oral Suspension (50 mg/mL) 92530 30 mL C.E.T. AQUADENT® FR3SH® Dental Solution 90516 16.9 fl oz. IVERHART MAX® Chew (ivermectin/pyrantel pamoate/praziquantel) - Display - Small 50104 10 Boxes of 6 Doses ANXITANE® (L-Theanine) Chewable Tablets - M & L 100 mg 10435 30 ct. BIOMOX® (amoxicillin) Tablets (50 mg) 92505 500 ct. C.E.T.® Enzymatic Oral Hygiene Chews for Dogs - Extra Small 90601 Approx.30 ct. IVERHART MAX® Chew (ivermectin/pyrantel pamoate/praziquantel) - Display - Medium 50106 10 Boxes of 6 Doses MOVOFLEX® Soft Chews S (2 gm) 10700 60 ct. BIOMOX® (amoxicillin) Tablets (100 mg) 92105 500 ct. C.E.T.® Enzymatic Oral Hygiene Chews for Dogs - Small 90603 Approx.30 ct. IVERHART MAX® Chew (ivermectin/pyrantel pamoate/praziquantel) - Display - Large 50108 10 Boxes of 6 Doses MOVOFLEX® Soft Chews M (4 gm) 10701 60 ct. BIOMOX® (amoxicillin) Tablets (200 mg) 92205 500 ct. C.E.T.® Enzymatic Oral Hygiene Chews for Dogs - Medium 90605 Approx.30 ct. IVERHART PLUS® (ivermectin/pyrantel) Flavored Chewables - Display - Small 0170DS 10 Boxes of 6 Doses MOVOFLEX® Soft Chews L (6 gm) 10702 60 ct. CLINTABS® (clindamycin hydrochloride) Tablets (25 mg) 902540 400 ct. C.E.T.® Enzymatic Oral Hygiene Chews for Dogs - Large 90607 Approx.30 ct. IVERHART PLUS® (ivermectin/pyrantel) Flavored Chewables - Display - Medium 0170DM 10 Boxes of 6 Doses PANCREZYME® Powder 821008 8 oz. CLINTABS® (clindamycin hydrochloride) Tablets (75 mg) 907520 200 ct. C.E.T.® Enzymatic Tartar Control Toothpaste - Beef CET201 2.5 oz (70 g) IVERHART PLUS® (ivermectin/pyrantel) Flavored Chewables - Display - Large 0170DL 10 Boxes of 6 Doses PANCREZYME® Powder 821012 12 oz. CLINTABS® (clindamycin hydrochloride) Tablets (150 mg) 915010 100 ct. C.E.T.® Enzymatic Tartar Control Toothpaste - Seafood CET202 2.5 oz (70 g) SENERGY™ (selamectin) (30mg) 50005 10 Boxes of 3 Doses REBOUND® Recuperation Formula for Cats 10851 5.1 fl oz. RILEXINE® (cephalexin) Chewable Tablets (150 mg) 07620 100 ct. C.E.T.® Enzymatic Toothpaste - Malt CET102 2.5 oz (70 g) SENERGY™ (selamectin) (60mg) 50010 10 Boxes of 3 Doses REBOUND® Recuperation Formula for Dogs 10850 5.1 fl oz. RILEXINE® (cephalexin) Chewable Tablets (300 mg) 07630 100 ct. C.E.T.® Enzymatic Toothpaste - Poultry CET101 2.5 oz (70 g) SENERGY™ (selamectin) (120mg) 50020 10 Boxes of 3 Doses TUMIL-K® (potassium gluconate) Powder 846004 4 oz. RILEXINE® (cephalexin) Chewable Tablets (600 mg) 07640 100 ct. C.E.T.® Enzymatic Toothpaste - Vanilla-Mint CET103 2.5 oz (70 g) SENERGY™ (selamectin) (240mg) 50040 10 Boxes of 3 Doses TUMIL-K® (potassium gluconate) Tablets 845100 100 ct. C.E.T.® Enzymatic Toothpaste - Trial Packet Dispenser CET002 12 g/25 ct. SENERGY™ (selamectin) (360mg) 50085 10 Boxes of 3 Doses VETASYL® Fiber Capsules (500 mg) VF410 100 ct. EAR HEALTH PAGE 8 C.E.T.® HEXTRA® Premium Oral Hygiene Chews for Dogs - Petite 90612 Approx.30 ct. SENERGY™ (selamectin) (15mg) Dog & Cat 50090 10 Boxes of 3 Doses ® ® EASOTIC® (hydrocortisone aceponate, miconazole nitrate, 09360 10 mL C.E.T. HEXTRA Premium Oral Hygiene Chews for Dogs - Medium 90614 Approx.30 ct. SENERGY™ (selamectin) (45mg) Cat 50095 10 Boxes of 3 Doses IN-CLINIC USE PAGE 25 gentaminicin sulfate) Otic Suspension for Dogs ® ® C.E.T. HEXTRA Premium Oral Hygiene Chews for Dogs - Large 90616 Approx.30 ct. SENERGY™ (selamectin) (60mg) Cat 50097 10 Boxes of 3 Doses EUTHASOL® (pentobarbital sodium and phenytoin 710101 100 mL EPIOTIC™ Advanced Ear Cleanser 003104 4 fl oz. C.E.T.® HEXTRA® Premium Oral Hygiene Chews for Dogs - Extra Large 90618 Approx.30 ct. sodium) Euthanasia Solution ® EPIOTIC™ Advanced Ear Cleanser 003108 8 fl oz. C.E.T.® Oral Hygiene Kit w/70 gm Poultry CET401 1 each PARASITICIDES PAGE 19 STELFONTA (tigilanol tiglate injection) 2 mg/mL - Bottle 10101 1 mL ® ® OTOMITE PLUS Ear Miticide 601712 0.5 fl oz. ® SUPRELORIN F (deslorelin acetate) Implant (4.7 mg) x2 44402 2 ct. C.E.T. Oral Hygiene Kit for Cats w/70 gm Seafood CET402 1 each EFFIPRO PLUS® Topical Solution for Cats 60463 10 Boxes of 3 Doses ® ® SUPRELORIN F (deslorelin acetate) Implant (4.7 mg) x5 44405 5 ct. C.E.T. Dual-Ended Toothbrush CET305 1 each EFFIPRO PLUS® Topical Solution for Dogs - Small 60473 10 Boxes of 3 Doses ® SKIN HEALTH PAGE 9 C.E.T. Fingerbrush w/12 gm Trial Packet CET301 1 each EFFIPRO PLUS® Topical Solution for Dogs - Medium 60483 10 Boxes of 3 Doses ® ® ® ALLERDERM OMEGADERM Essential Fatty Acids Supplement 14149 4 mL (28 ct.) C.E.T. Mini-Toothbrush w/12 gm Trial Packet CET302 1 each EFFIPRO PLUS® Topical Solution for Dogs - Large 60503 10 Boxes of 3 Doses ® ® ® ALLERDERM OMEGADERM Essential Fatty Acids Supplement 14186 8 mL (28 ct.) C.E.T. Cat Toothbrush w/ 12 gm Trial Packet CET303 1 each EFFIPRO PLUS® Topical Solution for Dogs - X-Large 60513 10 Boxes of 3 Doses ® ® ALLERGROOM Shampoo 12208 8 fl oz. C.E.T. Pet Toothbrush CET304 1 each EFFITIX® PLUS Topical Solution for Dogs - Toy 60520 10 Boxes of 3 Doses ® ® ALLERGROOM Shampoo 12216 16 fl oz. C.E.T. Pet Toothbrush Bulk Dispenser CET350 24 ct. EFFITIX® PLUS Topical Solution for Dogs - Small 60522 10 Boxes of 3 Doses ® ® ® ALLERMYL (Piroctone Olamine) Medicated Shampoo 002409 8 fl oz. C.E.T. VEGGIEDENT Flex Tartar Control Chews for Dogs - Extra Small 90085 30 ct. EFFITIX® PLUS Topical Solution for Dogs - Medium 60524 10 Boxes of 3 Doses ® ® ® ALLERMYL (Piroctone Olamine) Medicated Shampoo 002417 16 fl oz. C.E.T. VEGGIEDENT Flex Tartar Control Chews for Dogs - Small 90086 30 ct. EFFITIX® PLUS Topical Solution for Dogs - Large 60526 10 Boxes of 3 Doses ® ® ® EPI-SOOTHE Cream Rinse 001808 8 fl oz. C.E.T. VEGGIEDENT Flex Tartar Control Chews for Dogs - Medium 90087 30 ct. EFFITIX® PLUS Topical Solution for Dogs - X-Large 60528 10 Boxes of 3 Doses ® ® ® EPI-SOOTHE Cream Rinse 001816 16 fl oz. C.E.T. VEGGIEDENT Flex Tartar Control Chews for Dogs - Large 90088 30 ct. KNOCKOUT® Area Treatment 612014 14 oz. ® ® ® ® EPI-SOOTHE Shampoo 11708 8 fl oz. C.E.T. VEGGIEDENT FR3SH Tartar Control Chews for Dogs - Extra Small 90055 30 ct. KNOCKOUT® E.S. Area Treatment 612216 16 oz. ® ® ® ® EPI-SOOTHE Shampoo 11716 16 fl oz. C.E.T. VEGGIEDENT FR3SH Tartar Control Chews for Dogs - Small 90056 30 ct. KNOCKOUT® Room & Area Fogger 612106 6 oz. ® ® ® ® GENESIS (triamcinolone acetonide) Topical Spray 410508 8 fl oz. C.E.T. VEGGIEDENT FR3SH Tartar Control Chews for Dogs - Medium 90057 30 ct. PREVENTIC® Tick Collar for Dogs - 18" 609526 1 each ® ® ® ® GENESIS (triamcinolone acetonide) Topical Spray 410500 16 fl oz. C.E.T. VEGGIEDENT FR3SH Tartar Control Chews for Dogs - Large 90058 30 ct. PREVENTIC® Tick Collar for Dogs - 25" 609525 1 each ® ® ® KERATOLUX (Piroctone Olamine) Medicated Shampoo 002009 8 fl oz. C.E.T. VEGGIEDENT Zen Tartar Control Chews for Dogs - Extra Small 90075 30 ct. VIRBANTEL® (pyrantel pamoate/praziquantel) Flavored Chewables - Small Dogs & Puppies 54030 50 ct. ® ® ® KERATOLUX (Piroctone Olamine) Medicated Shampoo 002017 16 fl oz. C.E.T. VEGGIEDENT Zen Tartar Control Chews for Dogs - Small 90076 30 ct. VIRBANTEL® (pyrantel pamoate/praziquantel) Flavored Chewables - Medium & Large Dogs 51114 50 ct. KETOCHLOR® (Chlorhexidine Gluconate,
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia
    A publication of the PHARMACEUTICAL SERVICES DIVISION AND THE CLINICAL RESEARCH CENTRE MINISTRY OF HEALTH MALAYSIA MALAYSIAN STATISTICS ON MEDICINES 2008 Edited by: Lian L.M., Kamarudin A., Siti Fauziah A., Nik Nor Aklima N.O., Norazida A.R. With contributions from: Hafizh A.A., Lim J.Y., Hoo L.P., Faridah Aryani M.Y., Sheamini S., Rosliza L., Fatimah A.R., Nour Hanah O., Rosaida M.S., Muhammad Radzi A.H., Raman M., Tee H.P., Ooi B.P., Shamsiah S., Tan H.P.M., Jayaram M., Masni M., Sri Wahyu T., Muhammad Yazid J., Norafidah I., Nurkhodrulnada M.L., Letchumanan G.R.R., Mastura I., Yong S.L., Mohamed Noor R., Daphne G., Kamarudin A., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Omar I., Zoriah A., Fong Y.Y.A., Nusaibah A.R., Feisul Idzwan M., Ghazali A.K., Hooi L.S., Khoo E.M., Sunita B., Nurul Suhaida B.,Wan Azman W.A., Liew H.B., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Asmah J., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I., Ghazali I., Wan Abu Bakar Y., Wan Hamilton W.H., Ravichandran J., Zaridah S., Wan Zahanim W.Y., Kannappan P., Intan Shafina S., Tan A.L., Rohan Malek J., Selvalingam S., Lei C.M.C., Ching S.L., Zanariah H., Lim P.C., Hong Y.H.J., Tan T.B.A., Sim L.H.B, Long K.N., Sameerah S.A.R., Lai M.L.J., Rahela A.K., Azura D., Ibtisam M.N., Voon F.K., Nor Saleha I.T., Tajunisah M.E., Wan Nazuha W.R., Wong H.S., Rosnawati Y., Ong S.G., Syazzana D., Puteri Juanita Z., Mohd.
    [Show full text]
  • Basic Skin Care and Topical Therapies for Atopic Dermatitis
    REVIEWS Basic Skin Care and Topical Therapies for Atopic Dermatitis: Essential Approaches and Beyond Sala-Cunill A1*, Lazaro M2*, Herráez L3, Quiñones MD4, Moro-Moro M5, Sanchez I6, On behalf of the Skin Allergy Committee of Spanish Society of Allergy and Clinical Immunology (SEAIC) 1Allergy Section, Internal Medicine Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain 2Allergy Department, Hospital Universitario de Salamanca, Alergoasma, Salamanca, Spain 3Allergy Department, Hospital Universitario 12 de Octubre, Madrid, Spain 4Allergy Section, Hospital Monte Naranco, Oviedo, Spain 5Allergy Department, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain 6Clínica Dermatología y Alergia, Badajoz, Spain *Both authors contributed equally to the manuscript J Investig Allergol Clin Immunol 2018; Vol. 28(6): 379-391 doi: 10.18176/jiaci.0293 Abstract Atopic dermatitis (AD) is a recurrent and chronic skin disease characterized by dysfunction of the epithelial barrier, skin inflammation, and immune dysregulation, with changes in the skin microbiota and colonization by Staphylococcus aureus being common. For this reason, the therapeutic approach to AD is complex and should be directed at restoring skin barrier function, reducing dehydration, maintaining acidic pH, and avoiding superinfection and exposure to possible allergens. There is no curative treatment for AD. However, a series of measures are recommended to alleviate the disease and enable patients to improve their quality of life. These include adequate skin hydration and restoration of the skin barrier with the use of emollients, antibacterial measures, specific approaches to reduce pruritus and scratching, wet wrap applications, avoidance of typical AD triggers, and topical anti-inflammatory drugs. Anti-inflammatory treatment is generally recommended during acute flares or, more recently, for preventive management.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0099225A1 Freund Et Al
    US 20090099225A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0099225A1 Freund et al. (43) Pub. Date: Apr. 16, 2009 (54) METHOD FOR THE PRODUCTION OF Related U.S. Application Data PROPELLANT GAS-FREE AEROSOLS FROM (63) Continuation of application No. 1 1/506,128, filed on AQUEOUSMEDICAMENT PREPARATIONS Aug. 17, 2006, now Pat. No. 7,470,422, which is a continuation of application No. 10/417.766, filed on (75) Inventors: Bernhard Freund, Gau-Algesheim Apr. 17, 2003, now abandoned, which is a continuation (DE); Bernd Zierenberg, Bingen of application No. 09/331,023, filed on Sep. 15, 1999, am Rhein (DE) now abandoned. (30) Foreign Application Priority Data Correspondence Address: MICHAEL P. MORRIS Dec. 20, 1996 (DE) ............................... 19653969.2 BOEHRINGERINGELHEMI USA CORPORA Dec. 16, 1997 (EP) ......................... PCT/EP97/07062 TION Publication Classification 900 RIDGEBURY RD, P. O. BOX 368 RIDGEFIELD, CT 06877-0368 (US) (51) Int. Cl. A63L/46 (2006.01) (73) Assignee: Boehringer Ingelheim Pharma A63L/437 (2006.01) KG, Ingelheim (DE) (52) U.S. Cl. ......................................... 514/291; 514/299 (57) ABSTRACT (21) Appl. No.: 12/338,812 The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propel (22) Filed: Dec. 18, 2008 lant-free aerosols. US 2009/0099225A1 Apr. 16, 2009 METHOD FOR THE PRODUCTION OF 0008 All substances which are suitable for application by PROPELLANT GAS-FREE AEROSOLS FROM inhalation and which are soluble in the specified solvent can AQUEOUSMEDICAMENT PREPARATIONS be used as pharmaceuticals in the new preparations. Pharma ceuticals for the treatment of diseases of the respiratory pas RELATED APPLICATIONS sages are of especial interest.
    [Show full text]
  • Guidelines for the Management of Atopic Dermatitis in Singapore
    Management of Atopic Dermatitis—Yong Kwang Tay et al 439 Original Article Guidelines for the Management of Atopic Dermatitis in Singapore 1 2 Yong Kwang Tay, MMed (Int Med), FRCP (London), FAMS (Dermatology) (Chairman), Yuin Chew Chan, MBBS, MRCP (UK), FAMS (Dermatology), 3 4 5 Nisha Suyien Chandran, MRCP (UK), MMed (Int Med), FAMS (Dermatology), Madeline SL Ho, MBChB (Edin), MRCP (UK), MSc (London), Mark JA Koh, MBBS, 4 4 MRCPCH (UK), FAMS (Dermatology), Yen Loo Lim, MBBS, FRCP (Edin), FAMS (Dermatology), Mark BY Tang, MMed (Int Med), FRCP (Edin), FAMS (Dermatology), 6,7 Thamotharampillai Thirumoorthy, FRCP (London), FRCP (Glasg), FAMS (Dermatology) Abstract Introduction: Atopic dermatitis is a common, chronic pruritic condition affecting both children and adults, which has a negative impact on the quality of life. These guidelines were developed by an expert workgroup appointed by the Dermatological Society of Singapore, to provide doctors with information to assist in the management of their patients with atopic dermatitis. The workgroup members are experienced dermatologists with interest and expertise in eczemas. Materials and Methods: Workgroup members arrived at a consensus on the topics to be included. Relevant studies from the literature were assessed for best evidence, supplemented by the collective experience of the workgroup. Results: For mild atopic dermatitis, emollients, mild potency topical steroids and topical calcineurin inhibitors are recommended. For moderate-to-severe atopic dermatitis, the use of emollients, moderate- to-potent topical steroids, topical calcineurin inhibitors, wet dressings, antimicrobials for secondary skin infection, phototherapy, and systemic therapy (e.g. prednisolone, cyclosporine, azathioprine or methotrexate) may be warranted. Patients with moderate-to-severe atopic dermatitis should be managed in conjunction with a dermatologist.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Getting Under Skin of Canine Atopic Dermatitis Treatment
    Vet Times The website for the veterinary profession https://www.vettimes.co.uk GETTING UNDER SKIN OF CANINE ATOPIC DERMATITIS TREATMENT Author : Vanessa Schmidt, Tim Nuttall, Neil Mcewan Categories : Vets Date : June 7, 2010 Vanessa Schmidt, Tim Nuttall and Neil Mcewan discuss why long-term treatment plans for this condition need to be individualised, and how controlling flare factors is a key consideration CANINE atopic dermatitis (CAD) is a multifactorial disease. The best approach to managing this lifelong condition is a multimodal treatment plan that addresses each problem. The plan must aim to: • control flare factors; • improve skin barrier function; • provide allergen avoidance and allergen-specific immunotherapy (ASIT); • utilise anti-inflammatory treatment; and • tailor treatment for the individual patient. Human and canine atopic skin is not “normal”, even when in clinical remission. Long-term, low- frequency and regular treatment (often with topical glucocorticoids) in human AD ensures flares are less frequent and severe, and more easily managed. This helps prevent chronic AD development. It is likely this approach will also help CAD. 1 / 8 Flare factors Major flare factors in CAD are infections, ectoparasites, other hypersensitivities and environmental allergens. In humans, stress and environmental factors lower the pruritic threshold, and it is likely these play a role in CAD. Dog-appeasing pheromones, mood-modifying drugs and/or behavioural therapy may, therefore, be helpful in suitable cases. Observant owners may also identify and avoid other environmental triggers. Infections Recurrent staphylococcal and Malassezia dermatitis and/or otitis are common complications in CAD. The infections should be diagnosed on the basis of clinical signs, cytology and – where necessary – culture.
    [Show full text]
  • Using F-NMR and H-NMR for Analysis of Glucocorticosteroids in Creams
    KTH Royal Institute of Technology School of Chemical Engineering Degree project, in KD203X, second level, 2010 Using 19F-NMR and 1H-NMR for Analysis of Glucocorticosteroids in Creams and Ointments - Method Development for Screening, Quantification and Discrimination Angelica Lehnström Supervisors Monica Johansson, Medical Products Agency Ian McEwen, Medical Products Agency Examiner István Furó, Royal Institute of Technology Abstract Topical treatment containing undeclared corticosteroids and illegal topical treatment with corticosteroid content have been seen on the Swedish market. In creams and ointments corticosteroids in the category of glucocorticosteroids are used to reduce inflammatory reactions and itchiness in the skin. If the inflammation is due to bacterial infection or fungus, complementary treatment is necessary. Side effects of corticosteroids are skin reactions and if used in excess suppression of the adrenal gland function. Therefore the Swedish Medical Products Agency has published related warnings to make the public aware. There are many similar structures of corticosteroids where the anti-inflammatory effect is depending on substitutions on the corticosteroid molecular skeleton. In legal creams and ointments they can be found at concentrations of 0.025 - 1.0 %, where corticosteroids with fluorine substitutions usually are found at concentrations up to 0.1 % due to increased potency. At the Medical Products Agency 19F-NMR and 1H-NMR have been used to detect and quantify corticosteroid content in creams and ointments. Nuclear Magnetic Resonance, NMR, is an analytical technique which is quite sensitive and can have a relative short experimental time. The low concentration of corticosteroids makes the signals detected in NMR small and in 1H-NMR the signals are often overlapped by signals from the matrix.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Atopic Dermatitis Dogs 2013
    Atopic dermatitis; evidence and anecdotes. Where are we now in 2013? Dr Robert Hilton BVSc(Hons) MACVSc CertVD MRCVS www.skinvet.org Introduction In managing atopic dermatitis, this article is referring to dogs where food allergy (and non-allergic adverse reactions to food), flea allergy, sarcoptic mange and bacterial infection unrelated to allergy have been excluded and the clinical diagnosis of atopic dermatitis has been established. Atopic dermatitis is a clinical diagnosis based on logically excluding the other causes of chronic pruritus and having typical signs and history. Favrot’s 2010 criteria for canine atopic dermatitis: 1. Onset of signs under 3 years of age 2. Dog living mostly indoors 3. Glucocorticoid-responsive pruritus 4. Pruritus without clinical lesions at onset 5. Affected front feet 6. Affected ear pinnae 7. Non-affected ear margins 8. Non-affected dorso-lumbar area To differentiate dogs with AD from other causes of chronic pruritus, 5 satisfied criteria has a sensitivity of 85% and a specificity of 79%. Adding a sixth fulfilled parameter increases the specificity to 89% but decreases the sensitivity to 58%. In both dogs and humans, atopic dermatitis is associated with environmental allergens and significant defects in the epidermal barrier. A significant proportion of both dogs and humans (of the order of 30% plus) do not have significant levels of skin based or circulating immunoglobulin E; hence testing negative to both skin and blood allergen tests. Allergen tests are not used to diagnose atopic dermatitis; the only use for allergen testing is in making a desensitising vaccine. In dogs, low Ig is referred to as “atopic like-dermatitis atopic dermatitis” and in humans “intrinsic” atopic dermatitis”.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,859,774 B2 Hunt Et Al
    US008859.774B2 (12) United States Patent (10) Patent No.: US 8,859,774 B2 Hunt et al. (45) Date of Patent: Oct. 14, 2014 (54) HETEROARYL-KETONE FUSED (56) References Cited AZADECALN GLUCOCORTICOD RECEPTORMODULATORS U.S. PATENT DOCUMENTS 7,678,813 B2 3/2010 Clark et al. (71) Applicant: Corcept Therapeutics, Inc., Menlo 7,790,745 B2 9/2010 Yang et al. Park, CA (US) 7,928,237 B2 4/2011 Clark et al. 8.461,172 B2 6, 2013 Clark et al. (72) Inventors: Hazel Hunt, West Sussex (GB); Tony 8,598,154 B2 * 12/2013 Clark et al. .............. 514,210.21 2007/0281928 A1 12/2007 Clark et al. Johnson, Essex (GB); Nicholas Ray, 2008.OO70950 A1 3/2008 Benjamin et al. Essex (GB); Iain Walters, Nottingham 2010, O292.477 A1 11, 2010 Clark et al. (GB) 2012fO220565 A1 8, 2012 Clarket al. 2013,0225633 A1 8, 2013 Hunt et al. (73) Assignee: Corcept Therapeutics, Inc., Menlo Park, CA (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this EP O145121 A2 6, 1985 EP O37521.0 A1 6, 1990 patent is extended or adjusted under 35 JP 9-505030 A 5, 1997 U.S.C. 154(b) by 0 days. JP 2002-506032. A 2, 2002 JP 2002-544271 A 12/2002 (21) Appl. No.: 13/901.946 WO 95,04734 A1 2, 1995 WO 99.45925 A1 9, 1999 (22) Filed: May 24, 2013 WO OO6984.6 A1 11, 2000 WO O3,O15692 A2 2, 2003 WO O3,061651 A1 T 2003 (65) Prior Publication Data WO 2005/087769 A1 9, 2005 US 2014/OO38926A1 Feb.
    [Show full text]